Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
teriparatide + raloxifene
- Development stage
- Phase 4
- Lead developer
- Eli Lilly
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Administration
- Subcutaneous, Oral
01
Overview
Combination therapy of teriparatide and raloxifene for the treatment of postmenopausal osteoporosis. Teriparatide is a recombinant form of parathyroid hormone (PTH 1-34) that stimulates new bone formation, while raloxifene is a selective estrogen receptor modulator (SERM) that inhibits bone resorption. The combination aims to enhance bone formation and improve bone mineral density beyond what either medication can achieve alone.
02
Targets
ESR1 (ERα)ESR2 (ERβ)PTH1R (Parathyroid hormone/Parathyroid hormone-related peptide receptor type 1)
Beyond the preview
Go deeper on teriparatide + raloxifene.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on teriparatide + raloxifene.